US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.01

0.0000

Volume:76

Turnover:2.06K

Market Cap:2.43M

PE:- -

High:27.01

Open:27.01

Low:27.01

Close:27.01

52wk High:28.62

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:1.03

T/O Rate:0.08%

Dividend:0.45

Dividend Rate:1.67%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

Takeda receives FDA approval of NDA for Mimrylo

Health Care Down, but not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup

Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative

Simply Wall St.

NeuroThera Labs Hires European IR Firm to Expand Investor Reach

Oppenheimer biotech analysts hold an analyst/industry conference call

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

Becton Dickinson announces STANCE clinical trial enrollment milestone

Natera and Angiex partner in tumor testing using Signatera

Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs

Roche receives FDA approval for companion diagnostic tests for Ziihera

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

Revolution Medicines announces FDA approval of Rasonque in adults

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing

BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/NVIB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.0104,"timestamp":1788185608932,"preClose":27.0104,"halted":0,"volume":76,"delay":0,"changeRate":0,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"08-31 10:13:32 EDT","open":27.0104,"high":27.0104,"low":27.0104,"amount":2058.176672,"amplitude":0,"askPrice":27.31,"askSize":100,"bidPrice":27.25,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788206400000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.0104,"nav":26.953,"aum":2425792.32,"dividendRate":0.016729,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":26.96,"preClose":27.0104,"latestTime":"16:10 EDT","volume":6,"amount":162.0624,"timestamp":1787947804918,"change":-0.0504,"changeRate":-0.001866,"amplitude":0},"volumeRatio":1.033819},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.033819,"shares":90001,"dividePrice":0.45187,"high":27.0104,"amplitude":0,"preClose":27.0104,"low":27.0104,"week52Low":24.54,"pbRate":"--","week52High":28.621,"institutionHeld":0,"latestPrice":27.0104,"eps":0,"divideRate":0.016729,"volume":76,"delay":0,"ttmEps":0,"open":27.0104,"prevYearClose":25,"prevWeekClose":27.0104,"prevMonthClose":25.6004,"prevQuarterClose":25,"fiveDayClose":25.9412,"twentyDayClose":26.2307},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663588047","title":"Protagonist announces Takeda received U.S. FDA approval for MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663588047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663588047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 04:35","pubTimestamp":1788122107,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","BK4139","LFSC","BK4588","GDOC","IYH","TBXU","PINK","MRNX","IBB","TAK","PSCH","MRNY","RSPH","BK4585","NVIB","PTGX","BK4007","BBP","TECB","IEIH","FRTY","IDNA","MEDI","XLVX","SYNB","LABU","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663404203","title":"Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103","url":"https://stock-news.laohu8.com/highlight/detail?id=2663404203","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663404203?lang=en_us&edition=fundamental","pubTime":"2026-08-31 03:35","pubTimestamp":1788118510,"startTime":"0","endTime":"0","summary":"Tenax Therapeutics (TENX) announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 in patients with pulmonary hyp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tenax-therapeutics-announces-results-from-phase-3-level-trial-of-tnx-103-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tenax-therapeutics-announces-results-from-phase-3-level-trial-of-tnx-103-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","IDNA","BK4539","BK4139","LENZ","HYLG","GDOC","BK4007","TENX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019703","title":"Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019703","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019703?lang=en_us&edition=fundamental","pubTime":"2026-08-29 08:52","pubTimestamp":1787964735,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co ( ($JP:4502) ) just unveiled an announcement. Takeda has secured U.S. FDA approval for MIMRYLO (rusfertide), a first-in-cl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","BK4585","MEDI","MRNY","MRNX","NVIB","IDNA","BBP","PSCH","LFSC","TBXU","XLVX","BMED","RSPH","GNMX","TECB","IEIH","SYNB","GDOC","IBB","IYH","FRTY","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016033","title":"Takeda receives FDA approval of NDA for Mimrylo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016033","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663016033?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:00","pubTimestamp":1787958013,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia ve...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","MRNX","RSPH","BK4007","LFSC","BK4588","TAK","MEDI","IBB","SYNB","FRTY","XLVX","IDNA","BK4585","GDOC","TECB","BBP","MRNY","PINK","LABU","IEIH","NVIB","BMED","GNMX","PSCH","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663015241","title":"Health Care Down, but not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2663015241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663015241?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:22","pubTimestamp":1787952120,"startTime":"0","endTime":"0","summary":"Health-care companies fell, but not by as much as the broad market, as traders rotated into sectors less sensitive to interest-rate movements.BioNTech shares slid after the biotech firm scrapped a clinical trial for its mRNA cancer vaccine, marking the second setback this year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4581","BK4585","LABU","BK4588","NVIB","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705792","title":"Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705792","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662705792?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:22","pubTimestamp":1787898153,"startTime":"0","endTime":"0","summary":"Repligen recently reported past second-quarter 2026 results that exceeded earnings and revenue expectations and raised its full-year 2026 guidance, highlighting broad year-over-year growth across filtration, chromatography, proteins, and process analytics.\nAn interesting detail is that this operational momentum, accompanied by higher full-year forecasts and rising analyst estimates, may reinforce perceptions of Repligen’s business strength across multiple bioprocessing franchises.\nWe’ll now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1815336091.USD","LU0205194284.USD","NVIB","RGEN","LU0205193047.USD","LU0106261612.USD","LU0012050646.USD","XBIX","BK4121","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662403754","title":"NeuroThera Labs Hires European IR Firm to Expand Investor Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2662403754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662403754?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:02","pubTimestamp":1787878968,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an announcement. NeuroThera Labs Inc., a clinical-stage biotech subsidiary of SciSparc Ltd. listed ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX","EPV","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662871430","title":"Oppenheimer biotech analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2662871430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662871430?lang=en_us&edition=fundamental","pubTime":"2026-08-28 02:00","pubTimestamp":1787853615,"startTime":"0","endTime":"0","summary":"Biotech Analysts, along with the Co-Director of Stanford Amyloid Cente, discuss the full results from AZN/IONS‘s CARDIO-TTRansform trial on an Anal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XBIX","XBI","BK4588","NVIB","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085942","title":"AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085942","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085942?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:01","pubTimestamp":1787835660,"startTime":"0","endTime":"0","summary":"Video webcast now availablehere OCALA, Fla., Aug.  27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)(“AIM” or the “Company”) today announced that it participated in the Virtual Inv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/27/3352073/29489/en/aim-immunotech-participates-in-the-virtual-investor-why-now-on-demand-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","MEDX","IDNA","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662470993","title":"Becton Dickinson announces STANCE clinical trial enrollment milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2662470993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662470993?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:55","pubTimestamp":1787828139,"startTime":"0","endTime":"0","summary":"Becton Dickinson (BDX) announced a milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial eval...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/becton-dickinson-announces-stance-clinical-trial-enrollment-milestone-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/becton-dickinson-announces-stance-clinical-trial-enrollment-milestone-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1571399168.USD","LU0477156797.USD","LU1854104046.USD","LU1894683264.USD","LU0266013472.USD","MEDX","LU0511384066.AUD","LU0289961442.SGD","BDX","BK4588","LU0985489474.SGD","LU1059921491.USD","LU0006061336.USD","IDNA","NVIB","LU1150488135.SGD","LU0162691827.USD","LU0289739343.SGD","LU0985320562.USD","LU1854103824.USD","LU1894683348.USD","BK4082","LU1150488218.USD","LU0130518102.USD","LU0878866978.SGD","LU0068578508.USD","LU0072461881.USD","LU0648000940.SGD","IHI","LU0130103400.USD","GDOC","IE00BFXG1179.USD","BK4585","LU1201861165.SGD","LU0433182093.SGD","BK4504","LU1489326972.SGD","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662221703","title":"Natera and Angiex partner in tumor testing using Signatera","url":"https://stock-news.laohu8.com/highlight/detail?id=2662221703","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662221703?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:10","pubTimestamp":1787825446,"startTime":"0","endTime":"0","summary":"Natera (NTRA) announced a new Signatera collaboration with Angiex, a privately held biotech company developing a portfolio of Nuclear-Delivered Ant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-and-angiex-partner-in-tumor-testing-using-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-and-angiex-partner-in-tumor-testing-using-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065169927.USD","LU0963586101.USD","LU0345770993.USD","XBIX","LU0106261612.USD","LU0012050646.USD","BK4139","LU2065170008.USD","LU0345770308.USD","GNOM","NVIB","NTRA","LU2065171311.SGD","LU2264538146.SGD","LU2065171402.SGD","LU1064131342.USD","LU1988902786.USD","LU2065731478.USD","LU0053671581.USD","HELX","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662747010","title":"Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2662747010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662747010?lang=en_us&edition=fundamental","pubTime":"2026-08-27 05:47","pubTimestamp":1787780836,"startTime":"0","endTime":"0","summary":"Immatics ( ($IMTX) ) just unveiled an announcement. Immatics N.V., a Nasdaq-listed biotech company headquartered in Houston and Tübingen, focuses o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immatics-raises-161-million-in-completed-equity-offering-to-advance-prame-cancer-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immatics-raises-161-million-in-completed-equity-offering-to-advance-prame-cancer-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","NVIB","BK4585","LCLG","BK4588","BK4215","XBIX","REZ","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662874134","title":"Roche receives FDA approval for companion diagnostic tests for Ziihera","url":"https://stock-news.laohu8.com/highlight/detail?id=2662874134","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662874134?lang=en_us&edition=fundamental","pubTime":"2026-08-27 03:00","pubTimestamp":1787770816,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that it has received FDA approval for expanded use of its PATHWAY HER2 and VENTANA HER2 Dual ISH DNA Probe Cocktail tests. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-approval-for-companion-diagnostic-tests-for-ziihera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-approval-for-companion-diagnostic-tests-for-ziihera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","BK4007","TECB","GNMX","RHHBY","PINK","GDOC","IBB","FRTY","MRNX","IEIH","NVIB","BMED","MRNY","BK4585","BK4588","CANC","IYH","XLVX","BBP","LABU","IDNA","MEDI","RSPH","SYNB","HRTS","PSCH","TBXU","03165"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797746","title":"Revolution Medicines prices Rasonque at $39,800 for 30-day supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766320,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) disclosed that following FDA approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenoc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","BK4585","RVMD","IE00B4R5TH58.HKD","MEDI","MRNY","BBH","IE00BJT1NW94.SGD","LU0320765992.SGD","MRNX","NVIB","IE0002141913.USD","IDNA","PTH","LU0109394709.USD","BBP","PSCH","LFSC","TBXU","BK4139","IE00BJJMRZ35.SGD","XLVX","BMED","CANC","IE00B2B36J28.USD","RSPH","GNMX","TECB","IEIH","SYNB","GDOC","IBB","IE0009354923.USD","IE00BFTCPJ56.SGD","IYH","FRTY","IE0009355771.USD","LABU","BK4588","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662074659","title":"Revolution Medicines announces FDA approval of Rasonque in adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2662074659","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662074659?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:05","pubTimestamp":1787763925,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE once-daily oral tablets, for the treatment o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","XLVX","IE0009355771.USD","LABU","GDOC","LU0889565916.HKD","FRTY","IYH","CANC","BK4588","GNMX","SYNB","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","IBB","LU0320765992.SGD","IEIH","BBH","LFSC","IE00B2B36J28.USD","MEDI","TBXU","TECB","MRNX","PSCH","BK4139","BBP","MRNY","IE0002141913.USD","PINK","IDNA","IE0009354923.USD","RSPH","NVIB","BK4585","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BMED","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662714236","title":"IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2662714236","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662714236?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:30","pubTimestamp":1787747400,"startTime":"0","endTime":"0","summary":"Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones A patient treated with IMNN-001 will s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351335/0/en/imunon-to-host-2026-r-d-day-highlighting-phase-3-ovation-3-trial-and-the-clinical-potential-of-imnn-001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","BK4588","GDOC","BK4181","MEDX","HST","BK4585","BK4218","HYLG","IMNN","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662471428","title":"Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662471428","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662471428?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:30","pubTimestamp":1787747400,"startTime":"0","endTime":"0","summary":"If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351327/0/en/celcuity-submits-snda-to-fda-for-revtorpyk-gedatolisib-for-hr-her2-pik3ca-mutant-locally-advanced-or-metastatic-breast-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2931357623.SGD","IE0031619046.USD","BK4599","HR","BK4157","SRET","LABU","BK4203","AEIS","HYLG","LU0757428866.USD","NVIB","BK4585","IDNA","BK4139","ALT","LU2089985449.USD","LU1815336091.USD","BK4225","GDOC","IE00B7SZL793.SGD","MEDX","BK4588","LU1878469433.USD","IE00B66KJ199.SGD","LU0274383776.USD","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760410","title":"4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760410","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760410?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:13","pubTimestamp":1787724830,"startTime":"0","endTime":"0","summary":"4basebio UK Societas ( ($GB:4BB) ) has issued an update. 4basebio PLC, a UK-listed biotech focused on synthetic, cell-free DNA and mRNA for advance...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","DNA","BK4561","BK4139","VAQC","NVIB","BK4109","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530687","title":"BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530687?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669120,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIH...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","TBXU","MRNY","BMED","IBB","BBP","GNMX","GDOC","FRTY","LABU","MEDI","PINK","SYNB","BK4139","IEIH","BK4526","RSPH","PSCH","MRNX","ONC","IDNA","XLVX","LFSC","NVIB","TECB","IYH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175807","title":"U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175807","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175807?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:23","pubTimestamp":1787667780,"startTime":"0","endTime":"0","summary":"Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-li","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350636/0/en/u-s-fda-approves-ziihera-zanidatamab-hrii-with-and-without-tislelizumab-plus-chemotherapy-in-first-line-her2-advanced-gastroesophageal-adenocarcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTF","SBIT","BPI","BMED","CBTA","YBTC","MNRS","BCCC","BTCO","CBTO","BFJL","BITX","BTCL","GDOC","IBIT","BITU","LABU","BTRN","CBOY","BTC","CBXJ","EZBC","MAXI","CBOJ","CBOA","AEIS","DEFI","CBXO","BTCC","BFAP","XBTY","CBTJ","BTCW","BITI","BITY","BITB","ARKB","BRRR","GBTC","BITO","CRC","IDNA","CBTY","NVIB","HODL","FBTC","BTCI","CBXY","DFII","BTCZ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":131,"code":"91000000","status":"200"}]}}